Drug Development

Daniela Neubert is liquid chromatography analyst at OFI Technologie & Innovation GmbH in Vienna.

Nicole Steiner-ReischÃ¼tz is coordinator at OFI Technologie & Innovation GmbH in Vienna.

Michael Pyerin is head of pharma, medical devices, and hygiene at OFI Technologie & Innovation GmbH in Vienna.

Michael WashÃ¼ttl is head of packaging at OFI Technologie & Innovation GmbH in Vienna.

Michael Krainz is project manager for packaging at OFI Technologie & Innovation GmbH in Vienna.

Chrysoula Kanakaki is GC chromatography analyst at OFI Technologie & Innovation GmbH in Vienna.

Articles

Research suggests that radiation can have a significant impact on the composition and rheology of hydroxyethyl cellulose-based medicinal gels.

Evaluating the Impact of Sterilization on Gel Formulations

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Celgene, bluebird bio Partner on CAR-T Therapy

Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.

Novartis Gets Positive EMA Opinion on Biosimilar to J&J’s Remicade

EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).

Amgen, Allergan Score Positive EMA Opinion on Biosimilar to Roche’s Herceptin

Major countries will be ranked based on the potential for biopharma market growth, innovation, and competitiveness. 

bioLIVE to Launch Global Biopharma Country Ranking

MedPharm has received a multi-million dollar investment by Ampersand Capital Partners to diversify its service offering and regional coverage.

MedPharm Receives Investment from Ampersand Capital Partners

Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.

Hitachi to Manufacture Regenerative Medicines

The agreement gives IncoCell Tianjin, a wholly-owned subsidiary of China-based Boyalife Group, access to Cesca’s celluar processing contract development and manufacturing services.

Cesca Licenses CAR-T Cellular Processing Services to China’s Boyalife Group

The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.

Helix BioPharma Partners with ProMab on CAR-T Therapies

The company plans to install 4000-L disposable bioreactors from ABEC at its new commercial manufacturing facility in Wuxi city, China.

Formulation and Drug Delivery